ABSTRACT
In multiple clinical trials, patients who received drug-eluting stents instead of plain stents during percutaneous coronary interventions had rates of restenosis that were lower by roughly one half to three fourths, depending on how restenosis was defined and on the population studied. These stents will likely be used more and more as their indications evolve.
Footnotes
↵* Dr. Ellis has indicated that he has received grant or research support from the Cordis and Medtronic corporations and serves as a consultant for the Cordis, Boston Scientific, and Guidant corporations. This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.
- Copyright © 2004 The Cleveland Clinic Foundation. All Rights Reserved.
